MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival
2011

MicroRNA Expression in Multiple Myeloma and Its Association with Genetic Subtype and Survival

Sample size: 47 publication 10 minutes Evidence: moderate

Author Information

Author(s): Chi Jianxiang, Ballabio Erica, Chen Xiao-He, KuĊĦec Rajko, Taylor Steve, Hay Deborah, Tramonti Daniela, Saunders Nigel J, Littlewood Timothy, Pezzella Francesco, Boultwood Jacqueline, Wainscoat James S, Hatton Christian SR, Lawrie Charles H

Primary Institution: Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK

Hypothesis

The study investigates the role of microRNAs in the pathogenesis of multiple myeloma and their association with genetic subtypes and survival outcomes.

Conclusion

The study identified specific microRNA signatures associated with multiple myeloma that could serve as valuable resources for understanding the disease's pathogenesis and prognosis.

Supporting Evidence

  • 129 microRNAs were identified as being aberrantly expressed in multiple myeloma.
  • 39 microRNAs were associated with the pre-malignant condition MGUS.
  • Expression levels of specific microRNAs were distinct between genetic subtypes of multiple myeloma.
  • MicroRNA expression profiles could predict chromosomal abnormalities in over 85% of cases.
  • 32 microRNAs were associated with event-free survival in multiple myeloma patients.

Takeaway

This study looked at tiny molecules called microRNAs in patients with multiple myeloma to see how they relate to the disease and survival. They found that certain microRNAs can help predict how the disease will progress.

Methodology

Microarray analysis was used to study the microRNA profiles of purified tumor cells from patients with multiple myeloma, monoclonal gammopathy of undetermined significance, and healthy controls.

Potential Biases

Potential biases may arise from the selection of patient samples and the methods used for microRNA analysis.

Limitations

The study's findings may not be generalizable due to the specific patient population and the limited number of controls.

Participant Demographics

The median age of patients was 67 years, with a range from 43 to 89 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1745-6150-6-23

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication